## LRCX: Lam Research Corporation - XLK: Technology

### Executive Summary

No thesis match: MRS_20 3.3% below STRENGTH zone (4.0-10.0%); PEG 1.99 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($147.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Farmers Trust Co. Purchases 13,136 Shares of Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251215T101236 | Bullish | Relevance: 100%
- Farmers Trust Co. has increased its stake in Lam Research Corporation (NASDAQ:LRCX) by 30.1%, acquiring an additional 13,136 shares, bringing its total holdings to 56,710 shares valued at $7.59 million. This makes Lam Research the firm's 18th largest position, accounting for 1.3% of its portfolio. The semiconductor company recently beat Q3 earnings estimates and received several analyst target price increases, although insiders have been net sellers.

**2. Bernstein Analyst Reaffirms Buy Rating On Lam Research Corporation (LRCX)**
- Source: Insider Monkey | 20251212T085000 | Bullish | Relevance: 100%
- Bernstein analyst Stacy Rasgon reaffirmed a "buy" rating for Lam Research Corporation (NASDAQ: LRCX) with a $175 price objective, while Morgan Stanley's Shane Brett increased their price objective to $158 while maintaining an "Equal Weight" rating. The company is expanding its operations with a new $65 million office facility in Oregon, strengthening its research and development capabilities for the growing semiconductor industry. Lam Research is a major supplier of semiconductor wafer fabrication equipment and is expanding its market share in logic chip equipment, although the article suggests even greater potential in certain AI stocks.

**3. Lam Research Corporation $LRCX Holdings Increased by Jump Financial LLC**
- Source: MarketBeat | 20251210T120812 | Somewhat-Bullish | Relevance: 100%
- Jump Financial LLC significantly increased its stake in Lam Research Corporation (NASDAQ:LRCX) by 104.6% in the second quarter, now owning 46,338 shares valued at $4.51 million. Other institutional investors also adjusted their positions in the semiconductor company. Lam Research reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend of $0.26 per share.

**4. Federated Hermes Inc. Has $30.86 Million Stock Holdings in Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251210T095245 | Neutral | Relevance: 100%
- Federated Hermes Inc. significantly reduced its stake in Lam Research Corporation by 46.3% in the second quarter, bringing its total holdings to $30.86 million. Despite this, other institutional investors like Vanguard Group Inc., JPMorgan Chase & Co., and Geode Capital Management LLC increased their positions in the semiconductor company. Wall Street analysts maintain a "Moderate Buy" consensus rating for Lam Research, with a consensus price target of $152.87.

**5. Migdal Insurance & Financial Holdings Ltd. Decreases Stake in Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251215T130748 | Neutral | Relevance: 100%
- Migdal Insurance & Financial Holdings Ltd. significantly reduced its stake in Lam Research Corporation (NASDAQ:LRCX) by 68.4% in the second quarter, selling 6,409 shares and retaining 2,958 shares valued at $288,000. Despite this decrease, other major institutional investors like Vanguard Group Inc., State Street Corp, JPMorgan Chase & Co., and Geode Capital Management LLC increased their positions in the semiconductor company. The article also notes recent analyst ratings, stock performance, and insider selling activities at Lam Research.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $158 | $137 | +15% |
| 2025-11-25 | UBS | $175 | $165 | +6% |
| 2025-11-12 | Citigroup | $190 | $175 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 6 ($14.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+0.3%)
- Blackrock Inc.: 9.9% (+1.7%)
- JPMORGAN CHASE & CO: 4.8% (+47.4%)
- State Street Corpora: 4.8% (+0.4%)
- Geode Capital Manage: 2.7% (-0.5%)

### Key Risks

1. Heavy insider selling: $14M sold (6 transactions in 90 days).
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.99 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 62%, ROA 20%, margin 30%). Balance sheet: strong liquidity (2.2x), $1.6B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($14.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $202.4B |
| Beta | 1.78 |
| 52W Range | $56.32 - $169.69 |
| Short Interest | 3.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.99 |
| Forward P/E | 28.6 |
| Current P/E | 33.2 |
| YoY Growth | 15.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 3.3% (minimal 5-day change). Below STRENGTH zone by 0.7pp (needs >4.0% for momentum thesis). MRS_5 (-1.5%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.6% shows strong absolute momentum above own 20MA. Outperforming sector by 3.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.83), confirming momentum. RSI neutral at 54. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.34% (CS: 64) | Neutral |
| RSI_14 | 54.3 | Neutral |
| MACD Histogram | 0.83 | Bullish |
| vs SMA20 | 1.036x | Above |
| vs SMA50 | 1.054x | Above |
| vs SMA200 | 1.509x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $160.52
- **Stop Loss:** $147.02 (8.4% risk)
- **Target:** $174.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $11,878.48
- **Portfolio %:** 11.88%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-28 (Est: $1.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.22 | $1.26 | +3.3% |
| 2025Q2 | $1.21 | $1.33 | +10.4% |
| 2025Q1 | $1.00 | $1.04 | +4.1% |
| 2024Q4 | $0.88 | $0.91 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*